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An autoimmune response to acetylcholine receptor (AChR) 1 in the postsyn- 
aptic membrane of muscle appears to be responsible for impairment of neuro- 
muscular transmission in humans suffering from myasthenia gravis (MG) and 
animals immunized with purified AChR.  This paper  and the accompanying 
paper (1) investigate how the autoimmune response to AChR is initiated, how 
the cellular and humoral arms of the immune system act to impair neuromuscu- 
lar transmission, and how the muscle responds to the immunological assault on 
its AChR. In this paper we show that experimental autoimmune myasthenia 
gravis (EAMG) can be induced in rats as well by immunization with purified 
syngeneic AChR as by immunization with AChR purified from Electrophorus 
electricus (eel) electric organs, and that the EAMG which ensues in either case 
involves formation of antibodies to muscle AChR which bind to AChRs at end- 
plates  and  cause  a  net  reduction in  the  number of muscle AChRs.  In  the 
accompanying paper we show that antibody from rats immunized with AChR 
can cause EAMG  in  normal rats  by binding to  muscle AChR and  causing 
reduction in AChR content, in part by targeting the postsynaptic membrane for 
destruction by phagocytic cells.  In order to put these observations into proper 
context, general features of both MG and EAMG are reviewed in the introduc- 
tion of this paper. 
Immunization of mammals with AChR purified from electric fish induces EAMG (2-7). 
Rat antibodies to AChR from eel cross-react only slightly with AChR from rat muscle (8). 
In this paper we show that rats immunized with purified syngeneic AChR also develop 
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726  THE  JOURNAL OF  EXPERIMENTAL  MEDICINE " VOLUME  144, 1976 LINDSTROM~  EINARSON~  LENNON 9  AND  SEYBOLD  727 
EAMG. Specificity of the autoimmune reaction in this case is shown by the observation 
that antibodies to muscle AChR in these rats cross-react only slightly with AChR from 
Electrophorus.  These  results  show that  an  individual's  AChRs,  in  suitable  adjuvant 
conditions, can induce an autoimmune response. 
Rats develop two phases of EAMG in response to a  single injection of Electrophorus 
AChR in adjuvant. 8-10 days after immunization an acute phase of  muscular weakness is 
observed which may be fatal (3). Between 11 and 28 days there is remission from obvious 
weakness followed by a chronic phase of weakness which usually progresses to death (3). 
During the acute phase muscle end-plates are invaded by phagocytic cells (9, 10). These 
cells intrude between nerve and muscle and engulf  the postsynaptic membrane resulting 
in functional denervation of  up to 90% of the fibers (9, 10). Phagocytic cells disappear from 
the end-plate zone after the acute phase. Development of the chronic phase is associated 
with a dramatic increase in titer of serum antibody to muscle AChR (8). In the chronic 
phase the area of postsynaptic membrane is decreased and its folded structure simplified 
(9, 10). End-plates of animals with EAMG bind decreased amounts of 125I-a-bungarotoxin 
(5), exhibit decreased acetylcholine (ACh) sensitivity (11), increased curare sensitivity 
(12, 13), and  small  miniature  end-plate  potentials  (12). Antisera  from animals  with 
chronic EAMG inhibit the depolarizing response of muscle (11) and electroplax (8, 14) to 
cholinergic agonists in vitro. Few (14) or none (15) of the antibodies to AChR, depending 
on the serum used, are directed at the ACh binding site of the AChR. 
Human MG appears to resemble chronic EAMG more closely than acute EAMG. Both 
MG and chronic EAMG are characterized by weakness and fatigability  (3), increased 
curare sensitivity (12), small miniature end-plate potentials (12), simplified postsynaptic 
membrane structure,  reduced postsynaptic membrane area  (9,  10), and reduced l~sI-a- 
bungarotoxin binding at end-plates (16). Both rats with chronic EAMG and humans with 
MG also have comparable concentrations of serum IgG antibodies directed to determi- 
nants  on  their  respective  muscle  AChRs  other  than  the  ACh  binding  site  (8,  17). 
Decrementing electromyogram responses are a  diagnostic feature of MG which is rou- 
tinely observed in acute EAMG, but only in the most severely effected rats with chronic 
EAMG (12, 13). This has been attributed to the large safety factor for transmission in rats 
resulting from the fact that rat nerves release more ACh quanta than do human nerves 
(12). The massive phagocytic invasion of end-plates characteristic of acute EAMG is not 
observed in MG (18), though low levels of cellular infiltration might go undetected. 
Impairment of neuromuscular transmission  in  EAMG  and  MG  could  result  from 
decreased AChR content of muscle. Reduced postsynaptic membrane area (9, 10, 18) and 
decreased  ~25I-a-bungarotoxin  binding  to  end-plates  (5,  16)  are  consistent  with  this 
possibility.  However, antibodies bound to AChR in the membrane might also prevent 
toxin  binding  and  account for  decreased  ACh  sensitivity  (11) and  increased  curare 
sensitivity (12). Blockage of  AChR activity on muscle (11) and electroplax (8, 14) by serum 
from animals with EAMG is consistent with that possibility. In this paper we show that 
both antibody-mediated loss of AChR and antibody modification of AChR activity proba- 
bly occur in EAMG. In chronic EAMG the amount of AChR which can be extracted from 
muscle  is  greatly reduced,  and  much of the  AChR which  is  extracted  has  antibody 
attached,  but is still  capable of binding toxin.  Decreased AChR content of muscle in 
chronic EAMG suggests that antibody to AChR may induce "modulation" (19) of AChR. 
Antibody-induced removal of surface antigens has been demonstrated in other systems 
(19). Persistence of AChR unbound with antibody in rats with chronic EAMG having 
high serum titers of antibody suggests that antibody binding to AChR may also induce 
increased synthesis of AChR. 
Materials and Methods 
Preparation ofAChR.  AChR was solubilized from the electric organ of eel with the nonionic 
detergent  Triton X-100 and purified by affinity chromatography on Sepharose (Pharmacia  Fine 728  PATHOLOGICAL  MECHANISMS  IN  EAMG.I 
Chemicals  Inc.,  Piscataway,  N.  J.)  coupled  with the  a-neurotoxin of Naja naja  siamensis  as 
previously described (8, 20). To allow quantitative comparisons between rats, AChR was extracted 
from the total body musculature. Female Lewis rats were anesthetized with ether, exsanguinated, 
and decapitated.  After removal of skin,  tail,  and viscera,  the remainder of each carcass was 
homogenized for 1 min at high speed in a Waring blender at 4°C in 300 ml of 0.1 M NaC1, 0.01 M 
phosphate  buffer pH  7.0  (Waring Products  Div.,  Dynamics  Corp.  of America,  New  Hartford, 
Conn.). After centrifugation at 9 ×  10  ~ rpm for 20 min in a Sorvall GSA rotor (Ivan Sorvall, Inc., 
Norwalk, Conn.), the supernate was discarded. Homogenization and centrifugation were repeated 
on the pellet.  The second pellet was extracted in 160 ml 2% Triton X-100, 0.1  M  NaC1,  0.01 M 
phosphate buffer pH 7.0, 0.01 M NaN3 by homogenizing for 20 s to resuspend, followed by gentle 
shaking for 1 h.  After centrifugation at  l0  s g  for 30 min,  the resulting supernate was filtered 
through glass wool to remove floating lipid. Extracts of rats prepared in this way were used for 
quantitation of total AChR and antibedy-AChR complexes, and to provide AChR as antigen for a 
radioimmunoassay. For use as an immunogen, the AChR was further purified by the same affinity 
chromatography procedure used to purify AChR from eel.  18 of the group of 22 rats from which 
AChR was purified had EAMG induced by immunization with eel AChR.  The total amount of 
AChR extracted was 1.2 x  10  -9 mol (measured as 12~I-a-bungarotoxin-binding  sites). This included 
1.7 x  10 -~° mol ofAChR complexed with antibody (from the rats with EAMG). Purified AChR was 
obtained at a  15% yield (1.7 x  10  -~° mol including 1.4 ×  10  -H mol complexed with antibody). The 
amount of protein present was too small  to accurately measure without wasting much of the 
preparation. 
Inoculation of Rats.  Female Lewis rats aged 10 wk were injected intradermally with AChR 
emulsified in complete Freund's adjuvant and were given 2 ×  10  ~° BordeteUa pertussis  organisms 
subcutaneously, as described previously (3). One group of 27 rats (Table I) was immunized with 7.5 
x  10  -H  mol of eel AChR.  Three other groups totaling 73 rats were immunized with 60  ×10 -H 
mol of eel AChR (Fig. 1 and 2). Sp act of this AChR ranged from 3-5 ×  10  -6 mol 12sLa-bungarotoxin- 
binding sites/g protein. Three rats were immunized with 2.6  x  10 -H  mol of purified rat AChR 
(Table I). Three rats were given a dose of 2.6 x  10 -~ mol of purified rat AChR complexed in vitro 
with antibody (Table I). The complexes were prepared by mixing the purified rat AChR overnight 
with crude rat immunoglobulin (prepared as a  35% (NH4)2SO4 fraction of 0.53 ml of serum) from 
a  rat with EAMG. 
Clinical and Electrophysiological Tests.  Rats were observed daily for signs of EAMG which 
were scored, as previously described (3), on a scale ranging from 0 for normal through +  for weak 
grip and cry to + + +  for severe generalized weakness.  Electromyography was performed before 
and after intraperitoneal challenge with curare at doses that were without effect in normal rats (8 
~g or less), as previously described (13).  A decrementing muscle action potential response of 10% 
or more (fifth response compared with first) to repetitive supramaximal motor nerve stimulation 
at 5/s was regarded as evidence of EAMG (13). 
Antibody  Assays.  Titers of serum antibodies to AChR from eel and rat were  measured by 
indirect immunoprecipitation using l~sI-toxin-labeled AChR as antigen and goat anti-rat immuno- 
globulin as previously described (2,  8).  12sI-a-bungarotoxin was used at sp act of 2-4 x  10 ~ cpm/ 
mol. Antibody concentration was expressed in moles '25I-toxin binding sites precipitated per liter 
of serum. 
Quantitation of  AChR in Muscle.  The concentration of AChR in Triton-solublized rat muscu- 
lature was determined by labeling an aliquot of extracted material with ~25I-toxin (5  x  10  -~ M). 
The  specificity of binding of ~25I-toxin  to  AChR was  demonstrated  by  inhibition with  10 -3  M 
benzoquinonium. Labeled AChR was then precipitated by addition of excess rat anti-AChR serum 
followed by goat anti-rat antibody. This immunoprecipitation method gave the same values as 
direct measurement of benzoquinonium protectable binding of ~2sI-toxin using chromatography on 
Sephadex G-200, showing that ~sI-toxin binding to AChR was not prevented by the subsequent 
addition of excess anti-AChR antibody. Immunoprecipitation assays were performed in triplicate: 
0.5-ml aliquots of labeled extract (both with and without benzoquinonium) were mixed with 10 #l 
of a standard rat anti-AChR serum (titer =  1.7 x  10  -7 M). After overnight incubation, goat anti- 
rat immunoglobulin was added for 5 min (sufficient volume of a 35% (NH4)2SO~ fraction to form a 
maximum precipitate in 5 min). The resulting precipitate was pelleted by 2 min of centrifugation, 
washed in 1 ml of buffer (0.5% Triton X-100, 0.1 M NaC1, 0.1 M phosphate pH 7.0, 0.01 M NaNz), 
and pelleted again.  Radioactivity of the pellets was determined by ~-counting, and values with LINDSTROM,  EINARSON,  LENNON~  AND  SEYBOLD  729 
TABLE  I 
Comparative Immunogenicity of Eel and Syngeneic Muscle A ChR Proteins in Lewis Rats 
Incidence of EAMG 
Total  Amount per rat (× 10  -~ tool  ± SE) 
Dose  Serum antibody  Antibody-AChR 
Immunogen  (x I0 H mob  AChR in  muscle  complexes in 
Anti-eel  Anti-rat 
Clinical  EMG  muscle 
AChR  AChR 
None  -  0/6  nt  <0.5  <0.5  7.09 ± 0.20  0.173 ± 0.21 
Eel AChR  7.50  12/14  nt  1,510 ± 356  34.0 ± 21  2.07 ± 0.61  1.24  ± 0.55 
Rat AChR  2.58  3/3  3/3  11.8 ± 6.1  50.3 -* 28  1.84 _+ 0.32  0.906 ~ 0.14 
Rat  AChR-anti-  2.58  1/3  0/3  0.35 -+ 0.45  3.09 ± 1.9  3.09 ± 1.1  0.540 ± 0.19 
body  com- 
plexes 
Quantitation  of  serum antibody,  total  extractable  AChR, and  antibody-AChR complexes was  performed 35-49  days after  immunization. The 
amount of  antibody present  was calculated  assuming a serum vol  of  5  ml. 
benzoquinonium were subtracted from the test samples. The concentration of AChR per rat was 
expressed as moles '2sI-toxin-binding sites per liter. 
Detection and Quantitation  of Antibody-AChR  Complexes.  AChR was  identified  in  Triton- 
solubilized extracts of rat musculature by its specific binding of '25I-toxin as described above. The 
size of the toxin-binding material was estimated by sedimentation in a  sucrose gradient (20). The 
association of toxin-binding material with antibody was established by direct immunoprecipita- 
tion with goat anti-rat immunoglobulin. 
To triplicate  1-ml aliquots (with and without benzoquinonium) were added 5/~1 of normal rat 
serum  (as  carrier)  and  goat  anti-rat  immunoglobulin.  The  concentration  of  antibody-AChR 
complexes was expressed as moles '~sI-toxin binding sites precipitated per liter. 
Reduction  and Alkylation of Antibody In Situ.  In an attempt to increase the yield of AChR 
from muscle of rats with EAMG, homogenized tissues were subjected to reduction and alkylation 
to cleave bound antibody molecules and thereby circumvent possible insolubility of AChR which 
might be cross-linked with antibody. This was accomplished by the method used with success to 
increase to normal values the yield of AChR from eel electroplax treated  in vitro with antibody 
(21). Homogenized muscle was exposed for l0 min to 10  -3 M  dithiothreitol followed by 10 min with 
10  -2 M  iodoacetamide.  In other preparations more extreme conditions were used consisting of 60 
min 4  x  10 -~ M  dithiothreitol  in  10% homogenates of tissue followed by 60 min of 4  ×  10  -~ M 
iodoacetamide. 
Results 
Immunogenicity of  Syngeneic Muscle AChR.  Clinical and electrophysiologi- 
cal signs of EAMG were induced in rats by immunization with syngeneic AChR. 
None of the rats immunized with rat AChR exhibited early signs of weakness 
and fatigability characteristic of the acute phase of EAMG (3). However, 23-30 
days after immunization  all three rats inoculated with rat AChR alone devel- 
oped clinical  signs which were typical of chronic  phase EAMG  (3)  and  were 
severe and progressive. One of these showed a spontaneous decrement in muscle 
response to repetitive nerve stimulation,  while the other two exhibited decre- 
menting  responses  with  small  amounts  of curare  (13).  One  rat  of the  three 
immunized  with  antibody-AChR  complexes  developed  mild  clinical  signs  of 
EAMG commencing on day 31. On electromyographic testing on days 24 and 32 
none of these three rats had a  decrementing response,  even after curare chal- 
lenge. 
Titers of serum antibody to muscle AChR were considerably higher  in ani- 
mals  immunized  with  muscle AChR alone  than  in  animals  immunized  with 
antibody-receptor  complexes  (Table  I).  That  antibody-AChR  complexes were 730  PATHOLOGICAL  MECHANISMS  IN  EAMG.I 
less effective inducers of an antibody response is consistent with their being less 
effective  in  inducing  EAMG.  Anti-AChR  antibodies  induced  by  rat  muscle 
AChR reacted less with eel AChR than with rat AChR (Table I). The absolute 
amount of anti-muscle AChR antibody in the sera of rats immunized with either 
eel AChR or rat AChR was more than enough to bind to the total amount of 
AChR contained in a  rat's body. 
Decreased Content of  AChR in Rats with EAMG.  The total amount of AChR 
extractable  from  individual  normal  rats  in  an  age-  and  treatment-matched 
group was quite uniform (e.g., 7.09 _+ 0.2 x  10  -11 mol/rat for six rats). This value 
was significantly reduced in rats  with chronic  EAMG.  Of 14 rats immunized 
with 15 ~g of eel AChR, 9 had signs of chronic EAMG by day 39 when AChR 
content was determined. The mean value for total AChR extracted from these 14 
rats was 29% of the amount extracted from rats inoculated only with adjuvants 
(Table  I).  Further  experiments  presented  below  indicated  these  low  values 
represent an absolute decrease in the amount of AChR present in each rat. 
Identification  and  Quantitation  of Antibody-Receptor  Complexes  in  Mus- 
cle.  Triton-solubilized extracts from rats immunized 90 days earlier with 120 
~g of eel  AChR were labeled with  J25I-toxin  and  sedimented  on sucrose gra- 
dients. Instead of sedimenting as a single peak at 9.5S, like AChR from normal 
or  adjuvant-immunized  rats  (Fig.  1),  most  toxin-binding  material  extracted 
from rats with EAMG sedimented in broad peaks at 18-20S. This indicated that 
the toxin-binding material had a mol wt of approximately 6-8 x  105. Binding of 
toxin was inhibited in the presence of benzoquinonium. The high sedimentation 
value of this toxin-binding material suggested that AChR molecules (~2.5 x  105 
daltons)  from rats with chronic  EAMG might  be aggregated  into  small  com- 
plexes with a few molecules of antibody (1.5  x  l0 b daltons). 
That AChR in extracts of muscle from rats with EAMG was indeed complexed 
in situ with antibody was demonstrated by the ability of goat anti-rat immuno- 
globulin to directly precipitate the 125I-toxin-labeled material  (Table H). Thus, 
the specificity of the material binding ~2~I-toxin, as judged by its inhibition with 
benzoquinonium,  its large sedimentation coefficient, and its precipitability by 
anti-rat immunoglobulin antibodies provide strong evidence that AChR is com- 
plexed with antibody in situ in EAMG. The possibility that the antibody-AChR 
complexes were formed during the extraction process rather than  in vivo was 
ruled  out,  since  addition  of an  excess of exogenous  rat  anti-AChR  antibody 
during extraction of AChR from normal rat muscle did not yield antibody-AChR 
complexes detectable in the final extract. 
The fact that extracted antibody-AChR complexes were still capable of bind- 
ing ~2~I-toxin is evidence that anti-AChR antibody does not bind directly to the 
ACh-binding site. This fact also makes it unlikely that reduction in the amount 
of AChR extractable from rats with EAMG was apparent  (due to inhibition of 
toxin binding) rather than real.  Another possible explanation for the reduced 
absolute yield of AChR from rats with EAMG could be cross-linking of AChR by 
antibodies into  a  matrix  too large to be solubilized.  In that  case reduction of 
inter-heavy chain disulfide bonds of some of the antibodies cross-linking AChR 
should  cleave  them  into  half molecules  and  partially  break  up  the  matrix. 
Alkylation of the reduced disulfides should prevent recross-linking.  Poeduction 
and alkylation was performed on muscle homogenates from rats with chronic LINDSTROM,  EINARSON,  LENNON,  AND  SEYBOLD  731 
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FIG.  1.  Sucrose  density  gradient  centrifugation  of AChR  extracted  from  normal  and 
EAMG muscle. Aliquots (0.1 ml) of muscle extracts were incubated with ~25I-toxin (3 ×  10  -9 
M),  layered  on  sucrose  gradients,  and  centrifuged.  Fractions  21-34  at  the  top  of  the 
gradients containing unbound 12~I-toxin are not shown. (@) AChR extracted from adjuvant 
control rat muscle peaked in tube 15, indicating a sedimentation coefficient -9.5S.  (O, Q) 
AChR extracted  from  two  rats  with chronic EAMG  (90 days  after immunization) sedi- 
mented more rapidly, peaking at tube 4 or lower in the gradient. These 5-ml, 5-20% sucrose 
gradients were centrifuged 8.3 h  at 5  ×  10  ~ rpm in a  Beckman SW50.1  rotor (Beckman 
Instruments,  Inc.,  Fullerton,  Calif.).  Centrifugation for 4  h  failed to completely resolve 
control AChR from unbound ~25I-toxin, but then the antibody-AChR complexes sedimented 
in  the  middle  of the  gradient.  (Q)  appeared  as  two  peaks  -18S  and  -20S,  while  (O) 
appeared as a  single peak at -20S. 
TABLE II 
Typical Assay Results for Concentration of AChR and Antibody-AChR Complexes 
Binding of ~25I-a-bungarotoxin 
AChR assay  Antibody-AChR complex 
assay 
Test aliquots 
Aliquots plus benzoquinonium 
Difference ±  benzoquinonium 
AChR concentration 
2.07  ×  10  ~ cpm  1.77  ×  10  ~ cpm 
0.507  ×  104 cpm  0.195  ×  104 cpm 
1.56  ×  104 cpm  1.58  ×  104 cpm 
1.51  ×  10  -1° M  7.55  ×  10  -1~ M 
Assay  results  are  shown  for  a  single  rat  sacrificed  14  days  afeer  immunization with  120  ~g 
Electrophorus AChR assayed as described in Materials and Methods. Because of the high specific 
activity of the ~ssI-a-bungarotoxin used,  large numbers of cpm make possible accurate determi- 
nations despite the low amounts of AChR involved. 
EAMG  by  sequential  treatment  with  dithiothreitol  and  iodoacetamide  (21). 
However, this treatment did not increase the yield of AChR extracted from the 
muscle  (Table  III).  These data  also are  consistent  with  diminished  yields of 
AChR from rats with EAMG being due to a  decrease in AChR content of their 
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TABLE  III 
Effect of Reduction and Alkylation on Yield of Extracted AChR 
Before reduction and alkyla-  After reduction and alkyla- 
tion  tion 
AChR  AbAChR  AChR  AbAChR 
x  10  -~  ×  10  -~  +  10  -~  x  10  -~ 
mol/rat  mol/rat  mol/rat  tool/rat 
Chronic EAMG rats  1.20  0.752  1.13  0.714 
Chronic  EAMG  rats,  more 
intense reduction and al- 
kylation 
0.708  0.260  0.760  0.266 
Homogenates of the  two  rats  in  each  group  were  divided  in  half.  One  aliquot  was  extracted 
normally,  whereas  the  other  was  first  reduced  and  alkylated  as  described  in  Materials  and 
Methods. 
All  six  rats  immunized  with  syngeneic  muscle AChR  showed biochemical 
evidence of EAMG  (Table I).  As in rats immunized  with AChR from eel,  the 
amount of AChR extracted from muscle of rats immunized with rat AChR was 
greatly decreased.  Reduction in the amount of AChR was more pronounced in 
rats immunized with AChR alone than in rats immunized with antibody-AChR 
complexes.  In  rats  immunized  with  muscle  AChR  alone,  50%  of the  AChR 
extracted  was  complexed  with  antibody,  whereas  in  those  immunized  with 
antibody-AChR complexes, only 17% was complexed with antibody. 
Changes in Muscle AChR Content During the Course of  EAMG.  The results 
so far have established that an autoimmune response to muscle AChR, whether 
induced by immunization  with syngeneic or xenogeneic AChR, results in hu- 
moral antibodies to AChR being bound in vivo to AChR at the motor end-plate. 
As a result of the immune response to AChR, and perhaps through mechanisms 
mediated by these antibodies, the amount of AChR in muscle is greatly reduced. 
In order to ascertain the mechanisms involved in decreasing AChR content and 
the  importance  for  neuromuscular  transmission  of the  amount  of AChR  in 
muscle, we measured the changes in AChR content after immunization.  Fig. 2 
illustrates for individual rats, total body contents of muscle AChR, anti-muscle 
AChR antibody, and antibody-AChR complexes at intervals after immunization 
with purified eel AChR. These values are plotted in the same units (equivalent 
moles  125I-toxin-binding  sites)  to emphasize  the  quantitative  relationship  be- 
tween  the  three  factors  during  the  development  of EAMG.  Antibodies  with 
specificity for syngeneic muscle AChR were first detected in the serum 3 days 
after  immunization.  The  amount  of anti-AChR  antibody in  serum  increased 
slowly until day 20 and then increased very rapidly. The amount of anti-muscle 
AChR antibody in the serum of some rats with chronic EAMG exceeded their 
body content of AChR by a factor greater than 50. The amount of antibody to eel 
AChR was at all times 20-100 times greater than  the amount of anti-muscle 
AChR antibody.  AChR extracted from rat muscle was first found to be com- 
plexed  with  antibody  6  days  after  immunization.  The  percentage  of AChRs 
complexed in situ with antibodies increased  gradually,  from 1.4%  at day 6 to e- 
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DAYS  AFTER  IMMUNIZATION 
Fro.  2.  Changes in amount of antibody to AChR, antibody-AChR complexes, and AChR 
during the course of EAMG. Three groups of rats totaling 73 were immunized at day 0 with 
120  ~g of purified eel AChR.  On the indicated days animals were sacrificed.  Each point 
represents the average of two to six rats.  (A) (&---&) shows the average content of AChR 
from each rat. Bars indicate one standard deviation. (I.  • • II) shows the average content of 
antibodies to rat AChR assuming a serum vol of 5 ml. (C)--©) shows the average content of 
antibody-AChR complexes from each rat.  (B) (Q---O) indicates the average clinical state of 
the animals (ranging from 0 for normal to + + +  for moribund). 
more than 70% after day 28 (Fig. 2). By day 10 there were approximately equal 
amounts of antibody free in serum and complexed with muscle AChRs.  From 
day 6  to  8,  when  antibodies were first detected on muscle AChRs,  the total 
amount of AChR extractable was significantly decreased.  However, by days 9 
and 10 total amounts of AChR were in the normal range. The yield of AChR on 
days 11 and 12, and in some instances through day 14, was significantly greater 
than normal.  This increase was followed by a  progressive decrease in the total 
amount of AChR. Clinical weakness was first observed on day 7, with recovery 
in most animals by day 10, and recurrence starting approximately day 28. 734  PATHOLOGICAL  MECHANISMS  IN  EAMG.I 
Discussion 
The antigenicity of mammalian skeletal muscle AChR has been well estab- 
lished by specific interaction with antibodies derived from both patients with 
MG (8, 17, 22-24) and from animals immunized with AChR isolated from electric 
organs of fishes (2-8,  11,  14,  15). This paper presents the first evidence of the 
immunogenicity of mammalian muscle AChR. The immunogenicity of synge- 
neic muscle AChR was demonstrated in Lewis rats by its capacity to induce 
autoantibodies and clinical and electrophysiological  signs ofEAMG. Autoimmu- 
nity was induced by an amount of muscle AChR comparable to the amount of eel 
AChR required to induce EAMG (3). Complexing of muscle AChR with antibody 
reduced its immunogenicity. The immunogenicity  of mammalian muscle AChR 
may be enhanced by alterations in its structure during purification or emulsifi- 
cation in adjuvant. The demonstration that EAMG can be induced with synge- 
neic muscle AChR suggests that small alterations of  muscle AChR conformation 
or structure, e.g. associated with viral infections, could render this membrane 
protein immunogenic in man. For the ~spontaneous" occurrence of autoimmu- 
nity, predisposing immunogenetic factors may also be of importance. 
The method we have developed for quantitating the total amount of AChR 
extractable from a rat has provided a reproducible normal value for the AChR 
content of this inbred strain. The equation of'~'~sI-~-bungarotoxin-binding  sites" 
with ~'muscle AChRs" is justified by the fact that the toxin-binding material, 
which is solubilized in Triton X-100, has in common with nicotinic AChR of 
muscle (a) pharmacological specificity (as judged by inhibition with benzoqui- 
nonium), (b) antigenic identity (as judged by its precipitability with antibodies 
to purified AChR), and (c) molecular size (as judged by sucrose gradient sedi- 
mentation). The striking decrease in amount of AChR extracted from rats with 
chronic EAMG appears related to diminished content rather than technique of 
extraction. Firstly, interaction of AChR with antibody (either in vitro or in vivo) 
does not prevent binding of '25I-toxin to the isolated receptor (toxin labeled 
AChR is routinely used to detect AChR, and antibody-AChR complexes formed 
in vivo were shown to retain the ability to bind toxin). Secondly, if AChR were 
insoluble because of extensive cross-linking by antibodies in situ, reduction and 
alkylation would be expected to enhance its solubilization, as had been demon- 
strated in a  model system in which antibody was allowed to interact in vitro 
with AChR in situ in eel electroplax (21). 
The changes that occur in a rat's AChR content with time after immunization 
(Fig. 2) can be interpreted in terms of  what is known about the acute and chronic 
phases of EAMG. The initial decrease in AChR during the early acute phase of 
EAMG is no doubt largely due to extensive phagocytosis of the postsynaptic 
membrane by macrophages, which occurs at that time (9, 10). The muscle fibers 
during this acute stage of EAMG were shown to be functionally denervated, 
since direct nerve stimulation failed to elicit muscle responses in 90%  of the 
fibers (12). Therefore, the increased yield of AChR around days 10 and 12, by 
which time the inflammatory response at the motor end-plate is subsiding (9, 
10), is presumably due to synthesis of extrajunctional AChR which is known to 
occur as a consequence of denervation (25). It is known that blockage of neuro- 
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creases in extrajunctional AChR content of rat muscle (26). Repair spnthesis of 
junctional AChR probably contributes also  to  the  increased yield of AChR. 
Reinnervation after subsidence of  the macrophage invasion would be expected to 
terminate extrajunctional AChR synthesis. This probably accounts for the rapid 
return of AChR yields to normal around day 13. 
The continued gradual loss  of AChR after the acute phase of EAMG may 
involve a process analogous to antibody-induced modulation of surface antigens, 
which has been extensively studied in other systems such as the lymphocyte 
(19). Normally, AChR in the motor end-plate appears to turn over very slowly 
(27), whereas extrajunctional AChR synthesized before innervation or after 
denervation turns over with a  half-time of around 24 h  (25, 28). Binding of 
antibody to AChR at the neuromuscular junction may trigger the removal of 
junctional AChR by mechanisms normally reserved for extrajunctional AChR. 
Rapid synthesis of  junctional AChR in the chronic stage of EAMG would be a 
mechanism enabling a rat to survive in the chronic phase of EAMG and would 
also account for the constant small percentage of AChR which is not complexed 
with antibody despite high serum titers of antibody. The simplified morphology 
of the  postsynaptic membrane in  chronic EAMG may be  the  result  of the 
dynamic balance between antibody-induced turnover of AChR and increased 
synthesis of new AChR. 
In chronic EAMG a  large proportion of the remaining AChR is complexed 
with antibody. In support of the direct evidence for this, which we have provided 
in this paper by extraction of antibody-AChR complexes from rat muscle, we 
have also been able to localize antibody in the end-plates of rats with EAMG 
using  peroxidase-coupled anti-rat  gamma  globulin  as  a  stain  in  light  and 
electron microscopic studies (29). Because antibody to AChR applied to muscle 
(5, 11) or electroplax (4, 8, 14) in vitro inhibits AChR activity, it seems reasona- 
ble to expect that the functioning of these AChR bound with antibody in vivo 
may be partially or completely impaired. It is probable that there are several 
antigenic sites on AChR,  and antibodies bound to different determinants on 
AChR may result in effects on AChR activity ranging from negligible to com- 
plete block. Our results suggest that one site to which antibody is not bound is 
the  toxin-binding site  (i.e.,  acetylcholine-binding site).  Nonetheless,  in  the 
membrane, antibody bound at other sites might allosterically reduce or abolish 
binding of ACh. Antibody binding could leave ACh binding completely intact, 
but partially inhibit AChR activity by decreasing the duration of ionophore 
opening or its  conductance when open.  It  is  known that ACh analogues of 
differing affinity and efficacy differ from ACh in both the duration of channel 
opening which they induce (30) and in the conductance of the open channel (31). 
Since AChR function is effected by structural differences  in these small ligands, 
and even by membrane potential (32), it seems likely that binding of a large 
molecule-like antibody should alter AChR function. Thus it will be important to 
study the properties of AChR ionophores in these muscles. 
Because of the similarities between EAMG and human MG,  the methods 
described in this paper for examination of rat AChR have been applied to muscle 
from humans with MG. We have found greatly reduced amounts of AChR and 
found that much of the remaining AChR is complexed with antibody (Lindstrom 736  PATHOLOGICAL  MECHANISMS IN  EAMG.I 
and Lambert, manuscript in preparation). In further support of these results, we 
have recently shown extensive reduction in the area of postsynaptic membrane 
which can be stained with  ~-bungarotoxin coupled to peroxidase,  both in hu- 
mans  with  MG  and  rats  with  EAMG  (29).  These  results  constitute  critical 
similarities between rats with chronic EAMG and humans with MG, suggesting 
the critical importance of decreased AChR content to impairment of neuromus- 
cular transmission  in both diseases. 
Summary 
Immunization of Lewis rats with acetylcholine receptor (AChR) purified from 
either Electrophorus electricus electric organ or syngeneic rat muscle induced 
experimental autoimmune myasthenia gravis (EAMG). This was demonstrated 
by clinical  signs of weakness and by electromyographic evidence of impaired 
neuromuscular  transmission.  The amount of rat AChR required to induce an 
autoimmune response was comparable to the amount of eel AChR required.  In 
vitro complexing of rat AChR with antibody reduced its immunogenicity.  Au- 
toantibody to muscle AChR was present in serum and complexed with AChR in 
muscle.  Antibody  was  not  bound  to  the  ACh  binding  site  of AChR,  since 
antibody-AChR complexes extracted from muscle could still bind 125I-a-bungaro- 
toxin.  The  amount  of AChR extracted  from  muscle of rats  with  EAMG was 
diminished.  The amount of AChR and antibody-AChR complexes in muscle was 
measured at intervals after immunization with eel AChR. The amount of AChR 
decreased in rats with acute EAMG, then transiently  increased to more than 
normal  amounts during remission,  and finally decreased to only about 20% of 
normal  in rats with chronic  EAMG.  At least half of the AChR remaining  in 
animals  with chronic EAMG was complexed with antibody.  Thus,  both a  de- 
crease  in  amount  of AChR  and  the  formation  of antibody-AChR  complexes 
contribute to impairment  of neuromuscular transmission  in rats with EAMG. 
The  possible mechanisms  involved in the  changes  in AChR content  are dis- 
cussed. 
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